Biotechnology

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

From a one-room office to a regional logistics leader, Excel Courier marks four decades of driving critical industries like healthcare and tech.

ABEC's expanded group integrates advanced modeling and custom engineering to accelerate drug development, reduce risk, and boost manufacturing efficiency.

The architect of HUMIRA's launch and Horizon's $28B sale is now shaping the next wave of drug companies from within private equity. What does it mean?

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Preclinical data for CITY-RBP4 shows promise in treating Stargardt disease, a leading cause of juvenile blindness with no approved therapies.

A new global partnership aims to solve key bottlenecks in regenerative medicine by providing standardized, high-quality umbilical cord stem cells to researchers.

Empire Genomics & Molecular Instruments launch NISH, a fully automated system promising faster, clearer RNA-ISH results by preserving precious tissue samples.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

The Aesthetic Syndicate evolves into Manor, launching a national brand that fuses injectables with medically supervised GLP-1 therapy and holistic health.

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

A new partnership aims to solve banking woes for the multi-billion-dollar peptide and IV therapy industries, long deemed 'too risky' by traditional finance.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

Recognized on the CB Insights AI 100 list, Rhino Federated Computing pioneers a new era of secure, decentralized AI for highly regulated industries.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

Diagnostic leader Bracco enters the cell therapy market with BubbleGen, a novel microbubble tech that promises to streamline complex manufacturing.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.